Last edition
News about " next-generation cell therapies"
Acepodia Doses First Patient in Phase 1 Trial of ACE723 for Liver Cancer
Acepodia has dosed the first patient in its Phase 1 clinical trial of ACE723, an investigational dual-payload ADC for unresectable or metastatic hepatocellular carcinoma.
Next-generation Cell Therapies | 06/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members